(Total Views: 859)
Posted On: 07/08/2024 8:13:36 AM
Post# of 154003
Will be interesting to see what kind of deal Inventiva can pull off. Their cash will take them through the end of July. Lanifibranor has BTD in MASH with phase 3 top line readout for 2H 2026.
more recent attempts to secure cash through “the issuance of debt, equity and other instruments” have been unsuccessful, the company said.
A long-term solution could range “from partnerships to outright sale,” Stifel analysts said in a Sunday note. But finding a partner interested in MASH could be challenging given the recent “downstream evidence” of Eli Lilly’s dual GLP-1/GIP receptor agonist tirzepatide achieving MASH resolution with fibrosis data, they added.
https://endpts.com/inventiva-ramps-up-search-...-in-weeks/
more recent attempts to secure cash through “the issuance of debt, equity and other instruments” have been unsuccessful, the company said.
A long-term solution could range “from partnerships to outright sale,” Stifel analysts said in a Sunday note. But finding a partner interested in MASH could be challenging given the recent “downstream evidence” of Eli Lilly’s dual GLP-1/GIP receptor agonist tirzepatide achieving MASH resolution with fibrosis data, they added.
https://endpts.com/inventiva-ramps-up-search-...-in-weeks/
(2)
(0)
